Photographer: Victor J. Blue/Bloomberg
ArriVent Biopharma, a US-based biotech company that brings China-developed drugs to Western markets, raised $175 million in its upsized initial public offering (IPO) in the US, according to an announcement.
Photographer: Victor J. Blue/Bloomberg
ArriVent Biopharma, a US-based biotech company that brings China-developed drugs to Western markets, raised $175 million in its upsized initial public offering (IPO) in the US, according to an announcement.
